Dodge & Cox’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.38B | Sell |
24,250,826
-2,032,685
| -8% | -$285M | 1.86% | 13 |
|
|
2025
Q4 | $3.23B | Sell |
26,283,511
-3,849,620
| -13% | -$468M | 1.74% | 20 |
|
|
2025
Q3 | $3.34B | Sell |
30,133,131
-685,191
| -2% | -$77.9M | 1.8% | 17 |
|
|
2025
Q2 | $3.42B | Sell |
30,818,322
-1,876,469
| -6% | -$200M | 1.92% | 15 |
|
|
2025
Q1 | $3.66B | Sell |
32,694,791
-252,926
| -0.8% | -$26.1M | 2.09% | 11 |
|
|
2024
Q4 | $3.04B | Sell |
32,947,717
-98,020
| -0.3% | -$8.83M | 1.77% | 18 |
|
|
2024
Q3 | $2.77B | Sell |
33,045,737
-76,600
| -0.2% | -$5.84M | 1.57% | 23 |
|
|
2024
Q2 | $2.27B | Sell |
33,122,337
-45,150
| -0.1% | -$3.01M | 1.36% | 29 |
|
|
2024
Q1 | $2.43B | Sell |
33,167,487
-127,536
| -0.4% | -$9.81M | 1.41% | 24 |
|
|
2023
Q4 | $2.7B | Sell |
33,295,023
-238,715
| -0.7% | -$18.6M | 1.71% | 19 |
|
|
2023
Q3 | $2.51B | Sell |
33,533,738
-446,019
| -1% | -$34.3M | 1.69% | 18 |
|
|
2023
Q2 | $2.62B | Sell |
33,979,757
-722,005
| -2% | -$57.6M | 1.75% | 20 |
|
|
2023
Q1 | $2.88B | Sell |
34,701,762
-1,183,390
| -3% | -$98M | 1.96% | 19 |
|
|
2022
Q4 | $3.08B | Sell |
35,885,152
-484,100
| -1% | -$38.3M | 2.11% | 14 |
|
|
2022
Q3 | $2.24B | Sell |
36,369,252
-597,375
| -2% | -$37.7M | 1.7% | 18 |
|
|
2022
Q2 | $2.28B | Sell |
36,966,627
-60,003
| -0.2% | -$3.71M | 1.58% | 21 |
|
|
2022
Q1 | $2.2B | Sell |
37,026,630
-148,147
| -0.4% | -$9.47M | 1.34% | 30 |
|
|
2021
Q4 | $2.7B | Sell |
37,174,777
-91,915
| -0.2% | -$6.33M | 1.67% | 24 |
|
|
2021
Q3 | $2.6B | Buy |
37,266,692
+8,304,848
| +29% | +$583M | 1.7% | 23 |
|
|
2021
Q2 | $1.99B | Buy |
28,961,844
+10,499,694
| +57% | +$701M | 1.3% | 29 |
|
|
2021
Q1 | $1.19B | Buy |
18,462,150
+1,354,262
| +8% | +$87.3M | 0.85% | 45 |
|
|
2020
Q4 | $997M | Buy |
17,107,888
+4,500,035
| +36% | +$272M | 0.79% | 46 |
|
|
2020
Q3 | $797M | Buy |
12,607,853
+15,341
| +0.1% | +$1.06M | 0.73% | 51 |
|
|
2020
Q2 | $969M | Sell |
12,592,512
-2,518,449
| -17% | -$193M | 0.89% | 44 |
|
|
2020
Q1 | $1.13B | Sell |
15,110,961
-2,341,312
| -13% | -$162M | 1.22% | 35 |
|
|
2019
Q4 | $1.13B | Buy |
17,452,273
+15,752
| +0.1% | +$1.03M | 0.87% | 41 |
|
|
2019
Q3 | $1.11B | Buy |
17,436,521
+209,710
| +1% | +$13.7M | 0.91% | 40 |
|
|
2019
Q2 | $1.16B | Buy |
17,226,811
+153,131
| +0.9% | +$10.1M | 0.94% | 40 |
|
|
2019
Q1 | $1.11B | Buy |
17,073,680
+553,250
| +3% | +$36.8M | 0.91% | 41 |
|
|
2018
Q4 | $1.03B | Buy |
16,520,430
+70,249
| +0.4% | +$4.91M | 0.95% | 42 |
|
|
2018
Q3 | $1.27B | Buy |
16,450,181
+190,370
| +1% | +$14.4M | 0.97% | 39 |
|
|
2018
Q2 | $1.15B | Buy |
16,259,811
+814,350
| +5% | +$57.5M | 0.92% | 42 |
|
|
2018
Q1 | $1.16B | Buy |
15,445,461
+29,100
| +0.2% | +$2.31M | 0.94% | 41 |
|
|
2017
Q4 | $1.1B | Buy |
15,416,361
+5,506,630
| +56% | +$418M | 0.86% | 47 |
|
|
2017
Q3 | $803M | Buy |
9,909,731
+9,906,481
| +304,815% | +$758M | 0.65% | 55 |
|
|
2017
Q2 | $230K | Hold |
3,250
| – | – | ﹤0.01% | 173 |
|
|
2017
Q1 | $221K | Hold |
3,250
| – | – | ﹤0.01% | 176 |
|
|
2016
Q4 | $233K | Sell |
3,250
-500
| -13% | -$37.2K | ﹤0.01% | 177 |
|
|
2016
Q3 | $297K | Hold |
3,750
| – | – | ﹤0.01% | 165 |
|
|
2016
Q2 | $313K | Sell |
3,750
-3,870
| -51% | -$343K | ﹤0.01% | 159 |
|
|
2016
Q1 | $700K | Buy |
7,620
+3,870
| +103% | +$349K | ﹤0.01% | 142 |
|
|
2015
Q4 | $379K | Sell |
3,750
-500
| -12% | -$52K | ﹤0.01% | 164 |
|
|
2015
Q3 | $417K | Hold |
4,250
| – | – | ﹤0.01% | 155 |
|
|
2015
Q2 | $498K | Hold |
4,250
| – | – | ﹤0.01% | 146 |
|
|
2015
Q1 | $417K | Sell |
4,250
-260
| -6% | -$26.4K | ﹤0.01% | 159 |
|
|
2014
Q4 | $425K | Sell |
4,510
-290
| -6% | -$30K | ﹤0.01% | 162 |
|
|
2014
Q3 | $511K | Buy |
+4,800
| New | +$470K | ﹤0.01% | 154 |
|
Other funds holding GILD
VCM
VPM
Dodge & Cox's GILD Position: Q1 2026 in Review
Dodge & Cox reduced its Gilead Sciences (GILD) stake by 7.7% in Q1 2026, selling an estimated $285M and leaving 24,250,826 shares worth $3.38B. The position accounts for 1.86% of the portfolio, ranked #13.
Dodge & Cox first reported a position in GILD in Q3 2014 and has held it in 47 quarters since. The position peaked at $3.66B in Q1 2025. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Dodge & Cox held 24,250,826 shares of Gilead Sciences worth $3.38B as of Q1 2026.
- Dodge & Cox sold 2,032,685 Gilead Sciences shares in Q1 2026, an estimated $285M.
- Gilead Sciences made up 1.86% of Dodge & Cox's portfolio in Q1 2026, its #13 holding.
- Dodge & Cox first reported a position in Gilead Sciences in Q3 2014 and has held it in 47 quarters since.
- Dodge & Cox's Gilead Sciences position peaked at $3.66B in Q1 2025.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Dodge & Cox's 13F filing for Q1 2026, filed 14 May 2026.